INTRODUCTION

The cardioprotective/platelet inhibitory role of non-steroidal antiinflammatory drugs (NSAIDs) has been controversial, perhaps in contrast to the accepted prophylactic role of aspirin (114). That cardioprotective effect is attributed to the platelet aggregation inhibitory effects of aspirin and COX 1 active NSAIDS (10, 11, 13) and can be studied without requirement for massive numbers of patients. Such cardioprotection, however, has its own risks. Significant gastrointestinal toxicity is still present with the 75-81 mg aspirin dose and appears no less than that found with the higher doses once routinely utilized in treatment of arthritis (2, 8, 9). One study even reported that 4% of patients receiving aspirin had moderate to severe bleeding (14). The challenge with aspirin is that even with a 75 mg dose, the frequency of severe gastrointestinal hemorrhage is double that of placebo (2, 8, 9) and not different from that observed with COX 1 NSAIDs, in the absence of gastroprotection (e.g., misoprostol) (15).

Independent of the issue of relative safety of aspirin and COX 1 NSAIDs is that of medication regimen complexity. Polypharmacy is characteristic of the older patient (16). Given the inverse relationships of compliance and medication regimen complexity (17), any reduction in that complexity should be helpful. Reducing the required medication complexity could be accomplished if treatment of arthritis (or other NSAID indications) could also fulfill anti platelet/cardioprotective requirements. As NSAIDs have largely replaced aspirin in arthritis treatment, can they replace aspirin in the cardioprotective or at least platelet inhibition application? While the COX 2 selective agent rofecoxib (Vioxx) appears to uniquely increase cardiac risk.
there is no reason to expect cardioprotection from a COX 2 selective agent. COX 1 activity is required for platelet action (7). Obviously, the question of efficacy of anti-platelet effect is limited to COX 1 active agents.

The question therefore is efficacy. Several studies have suggested lack of benefit of NSAIDs as cardioprotective agents and that one (ibuprofen) even counteracts the cardioprotective effect of aspirin (3, 6, 7). However, the negative studies (3, 6) were seriously flawed, retrospective studies of prescription databases (19). They (3, 6) did not examine actual NSAID usage in the intracritical period, compliance with prescribed use, failed to consider over-the-counter aspirin-containing drug use and were heavily weighted towards ibuprofen usage (19). This contrasts with well controlled studies which documented the cardioprotective efficacy of naproxen, flurbiprofen and diclofenac (10, 11, 13, 20). Laboratory studies confirm this perspective. Ketoprofen effect on platelet function, measured by arachidonic acid induction of aggregation was equivalent to 325 mg aspirin (21).

Naproxen, flurbiprofen, ketoprofen and diclofenac have proven excellent arthritis treatment modalities, but share gastrointestinal toxicity with all COX 1 agents (22, 23). One approach to reducing gastrointestinal toxicity of COX 1 active agents is the gastroprotection achieved by prior ingestion of misoprostol (15). This was refined by the combination product, Arthrotec. The latter coats diclofenac with gastrointestinal protective misoprostol (24), simplifying the medication regimen. The misoprostol is released upon ingestion, prophylactically preparing the gastrointestinal protective tract for the NSAID.

As no study documents any differential cardioprotective efficacy of naproxen over voltaren (3, 6, 10, 11) and the gastrointestinal toxicity of Arthrotec is substantially less than that of naproxen (ingested without misoprostol preparation) (24), it seemed reasonable to examine the comparative platelet aggregation inhibitory effects of those agents.

METHODS

The study population consisted of 100 consecutive patients presenting to an arthritis centre, who had been diagnosed with one specific anti-platelet treatment indication: Presence of a circulating anticoagulant. The latter was recognized in the presence of anticardiolipin or anti-Beta-2-Glycoprotein I antibodies (25, 26). While platelet aggregation was prospectively evaluated, this was not a controlled study. Arthrotec (50 mg/day) was prescribed for those with known gastrointestinal risk factors (e.g., age, previous ulcer) (27). Individuals without risk factors were prescribed naproxen (250/1000 mg/day) or ketoprofen (50/200 mg/day), if they had an associated arthritis requiring NSAID treatment (dosage dependent upon arthritis treatment requirement) or aspirin (81 mg/day), if the only indication was prevention of complications related to the documented circulating anticoagulant. Those 15 individuals who had already been previously placed on 81-875 mg daily doses of aspirin, for cardioprotection by their primary care physicians, were maintained at those doses.

The number (variety) of ingested medications (not number of pills) ingested was recorded. The effect of aspirin and NSAIDs and possibility of immunoglobulin class (G, M or A) and antibody variety (cardiolipin or Beta-2-GPI) effect on platelet aggregation inhibition efficacy was examined by t test.

Blood was drawn 14-18 hours after the last NSAID or aspirin dose with a butterfly needle and multiple syringes and immediately placed into plastic tubes containing citrate anticoagulant (nine parts blood to one part anticoagulant) and mixed. Platelet rich plasma and platelet poor plasma were prepared by standardization with platelet count adjusted to 350,000 (28). Aliquots were incubated at 37 degrees for one minute before addition of aggregating agent: 500 \( \mu \)M arachidonic acid, 5 \( \mu \)M adenosine diphosphate, 0.8 \( \mu \)g/ml collagen. Aggregation was monitored for 8 minutes at 37 degrees with 1,000 rpm stirring following aggregating agent addition.

Platelet function was considered adequately suppressed if either ADP-induced platelet aggregation was reduced 80% from baseline, collagen-induced aggregation was reduced 90% or arachidonic acid induced aggregation was completely inhibited after one week of NSAID or aspirin therapy (1, 28). Individuals with inadequate response to NSAID (5 individuals) had repeat testing one week after initiation of 325 mg daily aspirin doses.

RESULTS

Average age of study population was 55 with women representing 60%. The majority had fibromyalgia, osteoarthritis and inflammatory arthri-
tis (i.e., spondyloarthropathy, rheumatoid arthritis, calcium pyrophosphate deposition disease). Five individuals had systemic lupus erythematosus. Total inhibition of platelet function was not observed. ADP induced platelet aggregation was suppressed by 80% in only 86% of individuals receiving aspirin, independent of doses ranging from 81 to 875 mg (Table I). This contrasted with limited inhibition of arachidonic acid induced aggregation and minimal interference with collagen induced platelet aggregation (Table I). NSAIDs produced satisfactory inhibition of ADP-induced platelet aggregation in 93%, collagen-induced in 33% and arachidonic acid-induced in 22%, independent of agent (ketoprofen, Naproxen or Arthrotec) used. Results did not vary with presence of anticardiolipin or anti-Beta-2-Glycoprotein I antibodies or with antibody class. Collagen and arachidonic acid inhibition criteria for adequacy of platelet function inhibition were not met for either aspirin or NSAIDs. Addition of aspirin to the NSAID regimen augmented platelet function inhibition in only one of five individuals. The median number of ingested medications was 6.5, ranging from 1 to 14.

### DISCUSSION

No significant difference was found between aspirin and NSAIDs in their effect on platelet function. Efficacy, as measured by 80% inhibition of ADP-induced platelet aggregation, was acceptable in 89%, independent of agent. Arthrotec performed equally as well as other NSAIDs and aspirin. To the extent that these agents affect platelet function, they are equivalent. In spite of a relatively short 75 minute serum half life (29), the voltaren component’s platelet effects are no less than those of longer active NSAIDs (ketoprofen half life = 1.4 3 hours; Naproxen half life = 12-15 hours) (29). Thus, the NSAID binding effect on the platelet is substantially greater than plasma half lives. While NSAIDs are reversible platelet inhibitors, their rate of dissociation from platelets appears to be sufficiently slow to maintain at least 18 hours efficacy. Efficacy (at least for platelet inhibition) suggested, the question therefore becomes which is the safest agent? There would appear to be no advantage to combining aspirin with a COX 1 NSAID. This would also address the polypharmacy issue, wherein 1-14 medications (median 6.5) were ingested. If an NSAID is required, regimen simplification suggests that a COX 1 agent replace aspirin. Use of a combination product (i.e., Arthrotec) has several advantages over other COX 1 NSAIDs in the at risk population. It also represents a simpler regimen than taking misoprostol three times a day and waiting 20 minutes to subsequently take an NSAID or aspirin dose. Lack of efficacy of aspirin on collagen and arachidonic acid-induced platelet aggregation and inadequate response in 14% of aspirin-treated individuals is bothersome, but routinely observed (4, 5, 28, 30). Absence of aspirin dose response in the current study mirrors previous reports (28, 31). Is aspirin good enough? An excellent, but moot question. At present, no agent has proven more efficacious than aspirin (32).

### CONCLUSION

If NSAIDs are equivalent in efficacy to aspirin, one could conclude that therapeutic regimens can be simplified in those individuals who require an
Aspirin for other problems. If those patients are in a high risk (for ulcer) group, then use of a COX1 active agent with gastroprotection (i.e., Arthrotec) would appear to be a safe alternative to COX1 active agent use. High (ulcer) risk patients, without other indications, should also probably receive an agent other than aspirin, given aspirin’s gastrointestinal toxicity (2, 8, 9).

As this is an uncontrolled study, results must be considered preliminary. Hopefully this analysis will stimulate the double blinded, controlled studies required not only to assess the platelet function effects but also to assess efficacy in blocking clinical events, both cardiovascular and gastrointestinal.

Acknowledgements

Appreciation is expressed to Mark Helbling II for logistical support in pursuit of this project.

SUMMARY

This study was conducted to assess the feasibility of COX1 NSAID substitution for aspirin for preventative therapy related to circulating anticoagulants, as manifest by inhibition of platelet aggregation. There was no difference in platelet aggregation inhibition between aspirin, naproxen, ketoprofen or diclofenac and misoprostol (in combination in the form of Arthrotec).

As COX1 NSAIDs appear equivalent in platelet inhibition efficacy to aspirin, therapeutic regimens can be simplified in those individuals who require an NSAID for other problems. Further, despite its short serum half-life, Arthrotec appears as effective as an antiplatelet agent. Controlled, double blind studies of efficacy in blocking clinical events (both cardiovascular and gastrointestinal) are recommended.

Key words - Circulating anticoagulant, platelet function, nonsteroidal antiinflammatory agents, aspirin.

Parole chiave - Anticoagulante circolante, funzione piastrinica, farmaci anti-infiammatori non steroidei, aspirina

REFERENCES

16. Gryfe CI, Gryfe BM. Drug therapy of the aged: The problem of compliance and the roles of physicians and
Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection